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Abstract
Inflammatory bowel disease [IBD] is characterized by chronic inflammation of the gastrointestinal 
tract. Medications such as corticosteroids, thiopurines, immunomodulators and biologic agents 
are used to induce and maintain remission; however, response to these drugs is variable and can 
diminish over time. Defective autophagy has been strongly linked to IBD pathogenesis, with evidence 
showing that enhancing autophagy may be therapeutically beneficial by regulating inflammation 
and clearing intestinal pathogens. It is plausible that the therapeutic effects of some IBD drugs are 
mediated in part through modulation of the autophagy pathway, with studies investigating a wide 
range of diseases and cell types demonstrating autophagy pathway regulation by these agents. 
This review will highlight the current evidence, both in vitro and in vivo, for the modulation of 
autophagy by drugs routinely used in IBD. A clearer understanding of their mechanisms of action 
will be invaluable to utilize these drugs in a more targeted and personalized manner in this diverse 
and often complex group of patients.
Keywords:  Autophagy; drugs; IBD; Crohn's disease
1. Introduction
The major inflammatory bowel diseases [IBD], Crohn’s disease [CD] 
and ulcerative colitis [UC], are characterized by chronic inflamma-
tion of the gastrointestinal [GI] tract and affect up to 1 in 250 people 
in the UK.1 A  recent National Health Service [NHS] review esti-
mated IBD treatment costs of £720 million per year,1 with roughly 
a quarter of these costs directly attributed to drug treatments.2 At 
present there is no cure for IBD, and medications are aimed at induc-
ing and maintaining remission of disease by modifying inflammatory 
processes.3 The efficacy of current drugs for the treatment of IBD 
continues to come under scrutiny, as response to treatment often 
diminishes over time, resulting in disease complications. A  recent 
review of European cohorts estimates that 10–35% of CD patients 
required surgery within 1  year of diagnosis and up to 61% by 
10 years.4 Development of new drugs is a long and expensive process 
associated with high failure rates; therefore, making better use of 
drugs that have already been approved for clinical use is essential. 
The Crohn’s and Colitis Foundation of America has recently high-
lighted this need for research into optimizing medical therapies,5 
with patient stratification and personalized medicine of key impor-
tance in this context.6 In order to improve the efficacy of existing 
drugs, a more comprehensive characterization of their mechanism of 
action is required. Here we give an overview of IBD drugs that have 
been linked to the modulation of autophagy, a cellular process that 
has been implicated in CD pathogenesis, and summarize what is cur-
rently known regarding their mechanism of action.
2. Aetiology of IBD
The aetiopathogenesis of IBD remains poorly understood but is 
almost certainly multifactorial in nature, with genetic predisposition, 
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environmental triggers [such as smoking, antibiotics and diet] and a 
dysregulated immune response to intestinal microflora all contribut-
ing.7 Genome-wide association studies [GWAS] have now identified 
multiple susceptibility loci for CD and confirmed the previously rec-
ognized association of nucleotide-binding oligomerization domain-
containing protein 2 [NOD2], genes involved in T cell-dependent 
immunity and autophagy, including autophagy-related protein 16-1 
[ATG16L1], immunity-related GTPase family M protein [IRGM] 
and leucine rich repeat kinase 2 [LRRK2].8 Genetic association with 
the transcription factor x-box-binding protein 1 [XBP1], a key com-
ponent of the endoplasmic reticulum [ER]-stress response, with both 
forms of IBD have also been identified and replicated.9 These genetic 
studies have led to an increase in research linking autophagy dys-
regulation to CD pathogenesis.
2.1. Autophagy
Autophagy is an intracellular process that degrades excessive, dam-
aged or aged proteins and organelles to maintain cellular homeosta-
sis.10 These homeostatic functions impact on many essential cellular 
processes including development and differentiation, survival, senes-
cence and innate and adaptive immunity, with dysregulated 
autophagy linked to a multitude of diseases.11 When macroautophagy 
[hereafter referred to as autophagy] is initiated, the isolation mem-
brane, an expanding lipid bilayer, forms a double membrane vesicle 
[the autophagosome] around the cargo to be degraded [Figure 1]. 
The mature autophagosome then fuses with a lysosome to form an 
autophagolysosome, in which lysosomal enzymes degrade the inner 
membrane and cargo. The process of autophagy is controlled by 
the coordinated activity of ATG [autophagy-related] proteins. The 
further detailed and complex molecular machinery involved in bio-
genesis of the isolation membrane and autophagosome is beyond 
the scope of this focused review and has been discussed comprehen-
sively elsewhere12; however, it is appropriate to highlight the role of 
ATG16L1 in this process. Two ubiquitin-like molecules, LC3 [micro-
tubule-associated proteins 1A/1B light chain 3A]/ATG8 and ATG12 
are involved in autophagosome biogenesis. LC3/ATG8 is conjugated 
to phosphatidylethanolamine [PE] to form lipidated LC3-II and is 
associated with autophagosome formation. ATG12 is conjugated to 
ATG5 and forms a complex with ATG16L1 [ATG16L1 complex]. 
The ATG16L1 complex is proposed to specify the site of LC3 lipida-
tion for autophagosome formation [Figure 1]13.
2.2. Autophagy signalling pathways
Autophagy is active at a basal level in most cell types to maintain 
homeostasis, and this activity is modulated in response to a myriad 
of stresses and stimuli that include starvation, hypoxia, infection 
and ER stress.14 Autophagy is largely regulated, but not exclusively, 
by the mTORC1 [mechanistic target of rapamycin complex 1] and 
Beclin1/B cell lymphoma 2 [Bcl-2] signalling pathways [Figure 2]. 
The mTORC1 pathway plays a central role in the inhibition of 
autophagy, for example blocking mTORC1 activity with the small 
macrolide antibiotic rapamycin stimulates induction of autophagy. 
Class I phosphatidylinositide 3-kinases [PI3K], Akt and Ras/Mek/Erk 
signalling pathways are involved in the activation of mTORC1 and 
subsequent inhibition of autophagy.14 mTORC1 inhibits autophagy 
via phosphorylation of Unc-51 like autophagy activating kinase 1 
[ULK1] and ATG13 to inhibit the ULK1-ATG13-FIP200 complex, 
which is important for initiation of autophagosome formation.15 
Conversely, AMP-activated protein kinase [AMPK] is involved in 
the inhibition of mTORC1 and stimulates autophagy via phospho-
rylation of ULK1 at sites distinct from mTORC1.16 Activated ULK1 
and AMPK subsequently phosphorylate Beclin1 for the induction 
of autophagy.16,17 Beclin1 induces autophagy through the formation 
of the class III PI3K complex consisting of Vps34-Vps15-Beclin1.18 
Interaction of the class III PI3K complex with ATG14 is important 
for recruitment of autophagy proteins, including the ATG16L1 com-
plex and LC3/ATG8, to the autophagosome membrane during early 
stages of the pathway [Figure 2].12
Beclin1 was originally identified as an interacting protein with 
Bcl-2 19, an anti-apoptotic protein that inhibits autophagy when 
it is in complex with Beclin1.20,21 In response to nutrient depriva-
tion, c-Jun N-terminal kinase [JNK]-1-mediated phosphoryla-
tion of Bcl-2 occurs, causing the dissociation of the Beclin1-Bcl-2 
complex and induction of autophagy.22 However, during periods 
of prolonged nutrient deprivation, increased levels of Bcl-2 phos-
phorylation prevent Bcl-2 from binding to and inhibiting pro-
apoptotic proteins including Bcl-2 associated X protein [BAX] and 
Bcl-2-antagonist/killer [Bak].23,24 Therefore, Bcl-2 phosphorylation 
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Figure 1. The autophagy pathway. During the initial stages of autophagy, the isolation membrane forms a double membrane vesicle [the autophagosome] 
around the cargo to be degraded. The mature autophagosome then fuses with a lysosome to form an autophagolysosome, in which cargo are degraded by 
lysosomal enzymes and subunits are recycled. Autophagy is controlled by the coordinated activity of ATG proteins. Two ubiquitin-like molecules, LC3 and 
ATG12, are involved in autophagosome biogenesis. LC3 is conjugated to PE to form lipidated LC3-II and is associated with the autophagosome outer membrane. 
ATG12 is conjugated to ATG5 and forms a complex with ATG16L1 [ATG16L1 complex]. The ATG16L1 complex is proposed to specify the site of LC3 lipidation 
for autophagosome formation.
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can act as a switch between autophagy, a pro-survival response to 
cellular stress and apoptosis, a mechanism to limit damage to neigh-
bouring cells under conditions of prolonged stress.24 A  rheostat 
model proposed by Pattingre et al.20 suggests that when autophagy 
exceeds physiological levels, then autophagic-cell death can occur 
due to over-digestion of essential cellular components. The complex 
relationship between autophagy and apoptotic cell death has been 
reviewed elsewhere.25
3. Autophagy and Crohn’s Disease
Xenophagy [a specific type of autophagy that degrades microorgan-
isms] is central to the innate immune response. It can target and 
degrade intracellular pathogens, stimulate the production of host 
defence peptides and present antigens to initiate the adaptive immune 
response.26 During infection, microbe-associated molecular patterns 
[MAMPs] are detected by a family of proteins called pattern recog-
nition receptors [PRRs] located within host cells. PRRs involved in 
xenophagy include the Nod-like receptors [NLRs], Toll-like receptors 
[TLRs] and sequestosome 1/p62-like receptors [SLRs] 27.
The PRR NOD2 was the first gene to be linked to CD suscep-
tibility in 2001,28–30 with the three most common CD-associated 
NOD2 single nucleotide polymorphism [SNP] variants [R702W, 
G908R and L1007f/s] identified in roughly one-third of patients.31 
Furthermore, homozygous mutation of the NOD2 gene increases 
the risk of developing CD 20- to 40-fold.31,32 The NOD2 L1007f/s 
variant is unable to detect muramyl dipeptide [MDP], a compo-
nent of bacterial cell walls, which results in deficient nuclear factor 
kappa-light-chain-enhancer of activated B cells [NFκB] signalling 
and host defence peptide secretion.33 In 2007 the first autophagy 
gene, ATG16L1, was linked to CD susceptibility,34 followed by the 
identification of variants in autophagy genes including IRGM and 
LRRK2.8 An SNP identified in ATG16L1, that encodes for a sin-
gle amino acid substitution [T300A],34 has been modelled in hypo-
morphic mice.35 These mice do not spontaneously develop intestinal 
inflammation but do show evidence of Paneth cell dysfunction that 
is similar to Paneth cells from patients homozygous for the T300A 
allele.36 A recent functional study using a T300A knock-in mouse 
model has demonstrated that the T300A variant creates a caspase 
cleavage site, making ATG16L1 more susceptible to caspase-3-me-
diated degradation.37
The majority of functional studies have focused on NOD2 and 
ATG16L1, which are among the strongest risk factors in CD. These 
studies have reported decreased autophagy levels in a range of cell 
types derived from CD patients, and cells harbouring NOD2 L1007f/s 
or ATG16L1 T300A variants exhibit a number of disrupted functions 
linked to autophagy, including impaired autophagosome formation 
and degradation of cytoplasmic microorganisms, defective presenta-
tion of bacterial antigens to CD4+ T cells and alterations in Paneth cell 
granule formation.33,38–41 Importantly, in intestinal epithelial cells and 
dendritic cells [DCs] that harbour the NOD2 L1007f/s or ATG16L1 
T300A variants, MDP-induced autophagy is diminished, leading to 
ineffective killing of pathogens such as Salmonella typhimurium, 
Shigella flexneri and Adherent Invasive Escherichia coli [AIEC].33 It 
has been suggested this may be due to the inability of NOD2 L1007f/s 
to recruit ATG16L1 T300A protein and the autophagy machinery to 
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Figure 2. Autophagy regulation. The central pathways in autophagy regulation are mTORC1 and Beclin1/Bcl-2. class I PI3K, via Akt and Ras/Mek/Erk signalling 
pathways phosphorylate Tuberin [TSC2] to promote Rheb-dependent activation of mTORC1. When active, mTORC1 inhibits formation of the ULK1-ATG13-
FIP200 complex, which is necessary for initiation of autophagy. Conversely, AMPK is involved in the inhibition of mTORC1 and stimulates autophagy via 
phosphorylation of ULK1 at sites distinct from mTORC1. Bcl-2 is dissociated from Beclin1 due to JNK-1-dependent phosphorylation of Bcl-2. Bcl-2 is then free 
to inhibit apoptosis through binding of BAX and Bak. Beclin1 is free to bind Vps34-Vps15 [the mammalian homologue of Vps15 is p150] to induce autophagy. 
The Vps34-Vps15-Beclin1 complex binds to ATG14L to induce further ATG protein recruitment and elongation of the isolation membrane in the initial stages of 
autophagy. Activated ULK1 and AMPK can also directly phosphorylate Beclin1 for the induction of autophagy [not shown].
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sites of bacterial entry at the cytoplasmic membrane.42 The increased 
levels of pro-inflammatory cytokines observed in CD patients have also 
been linked to autophagy dysregulation. Loss of functional ATG16L1 
protein results in increased pro-inflammatory IL-1β and IL-18 produc-
tion in murine studies39 and in human peripheral blood mononuclear 
cells.40 It has been suggested that when bound to NOD2, ATG16L1 
acts as a modulator of NOD2 activity, shifting the balance between 
autophagy and cytokine production; loss of functional ATG16L1 
shifts NOD2 activity towards pro-inflammatory signalling 40. 
Autophagy is required for presentation of antigens derived from 
degraded bacterial components to the adaptive immune system.26 This 
is of particular importance as dysregulation of T-cell responses are a 
key feature of CD pathogenesis. DCs from CD patients expressing the 
NOD2 L1007f/s or ATG16L1 T300A variants have disrupted antigen 
sampling and processing41 and are incapable of antigen presentation 
via major histocompatibility complex [MHC] II.33
Little is known about the function of IRGM and LRRK2 in CD. 
A deletion polymorphism immediately upstream of IRGM found in 
strong linkage disequilibrium with the most strongly CD-associated 
SNP, causes IRGM to segregate into CD risk variant [deletion] and 
protective variant [no deletion].43 Subsequently it has been shown that 
a family of microRNAs [miRNAs], miR-196, that is overexpressed in 
the inflammatory intestinal epithelia of individuals with CD, down-
regulates the IRGM protective variant but not the risk-associated 
variant. Functionally, the loss of IRGM protective variant expression 
compromises autophagy and control of the intracellular replication of 
CD-associated AIEC.44 Interestingly, a recent study has placed IRGM 
in a central role for the orchestration of core autophagy machinery 
in response to microbial infection.44 It was shown that IRGM regu-
lates the formation of a complex containing NOD2 and ATG16L1 
that is necessary for the induction of xenophagy. The interaction of 
IRGM with NOD2 also stimulates phosphorylation cascades involv-
ing AMPK, ULK1 and Beclin1 that regulate autophagy initiation 
complexes.44 LRRK2 expression is enriched in human immune cells 
and is increased in colonic biopsy specimens from patients with CD.45 
Functionally, LRRK2 can enhance NFκB-dependent transcription, 
whereas small interfering RNA [siRNA] knockdown of LRRK2 in 
RAW 264.7 macrophages interferes with reactive oxygen species pro-
duction and bacterial killing.45
Common upstream signalling pathways regulate autophagy; how-
ever, its activation can have different functional outcomes that oper-
ate in a cell-type specific manner. Consistent with this conditional 
knockout mouse models of autophagy genes ATG16l1 and ATG5 are 
selectively important for the biology of the Paneth cell, with notable 
abnormalities observed in the granule exocytosis pathway.36 IRGM1-
deficient mice also exhibit abnormalities in Paneth cell location and 
granule morphology, accompanied with increased susceptibility to 
inflammation in the colon and ileum.46 LRRK2 deficiency confers 
enhanced susceptibility to experimental colitis in mice; however, this 
was associated with enhanced nuclear localization of the transcrip-
tion factor nuclear factor of activated T cells [NFAT1], important for 
regulating innate immune responses.47 Specifically, it was found that 
there was aberrant activation of bone marrow-derived macrophages 
from the LRRK2 deficient mice following exposure to various stimu-
lators of innate immunity. Clearly, a comprehensive understanding of 
the cell-specific nature of autophagy and autophagy-related proteins 
is essential for understanding its role in IBD.
3.1. ER stress and autophagy
ER stress results from unfolded and misfolded protein accumulation 
in the ER, with cells that naturally secrete large amounts of protein, 
such as Paneth cells, being more susceptible to ER stress.48 The abil-
ity of highly secretory cells to respond to and resolve the ER stress 
depends on the unfolded protein response [UPR].48 Genetic studies 
have identified several ER stress/UPR genes that are associated with 
IBD,49 most notably XBP1, and there is evidence that ER stress lev-
els are increased in the intestines of patients with IBD.9 Autophagy 
activity is high in Paneth cells50 and can act to counterbalance ER 
stress 51; therefore ER stress is a significant risk when the UPR or 
autophagy is not functional. Consistent with this, targeted deletion 
of either XBP1 or ATG16L1 in intestinal epithelial cells is asso-
ciated with severe spontaneous CD-like transmural ileitis if both 
genes are compromised.50 Importantly, in Paneth cells of patients 
harbouring an ATG16L1 T300A risk allele, the ER-stress markers 
78 kDa glucose-regulated protein [GRP78] and phospho-eukaryotic 
initiation factor 2 α subunit [pEIF2α] were highly expressed.52 This 
has led to suggestion that the ATG16L1 T300A variant may define 
a specific subtype of patients with CD, characterized by Paneth cell 
ER stress, which correlates with bacterial persistence and reduced 
antimicrobial functionality.52 Interestingly, a recent study has dem-
onstrated a direct link between NOD1/2 and ER stress-induced 
inflammation.53 In mouse and human cells, the ER stress induc-
ers thapsigargin and dithiothreitol trigger the production of the 
pro-inflammatory cytokine IL-6 in a NOD1/2-dependent manner. 
Furthermore, IL-6 production induced by the intracellular patho-
gen Brucella abortus, which also induces ER stress, was dependent 
upon NOD1/2-signalling. Therefore, it is significant that major risk 
factors for CD, ATG16L1 and NOD2, functionally intersect with 
ER stress and the UPR. The convergence between autophagy and 
ER stress provides new opportunity for the treatment of IBD. For 
example, modulation of the UPR in combination with autophagy 
inducers is a promising therapeutic strategy.
3.2. Current IBD drugs
The mechanism of action of current IBD drugs remains incompletely 
understood [Table 1]. However, progress has been made in recent 
years towards characterising their effects, with the modulation of 
immunoregulatory signalling pathways often linked directly or indi-
rectly to the autophagy response [Table 2]. Importantly these het-
erogeneous studies have been conducted in a wide variety of disease 
settings and cell types; highlighting the need to explore the effect of 
these drugs on autophagy pathway activity in the context of IBD.
3.3. Corticosteroids
The first-line treatment for CD and UC is often corticosteroids. 
Corticosteroids downregulate pro-inflammatory cytokines including 
IL-1, IL-6 and tumor necrosis factor alpha (TNFα), by inhibiting the 
transcription of genes involved in their production and affecting the 
stability of messenger RNA [mRNA] to inhibit protein expression.54 
Furthermore, inflammatory signalling induced by NFκB is decreased 
due to interaction with corticosteroid receptors.54 Although there is 
limited knowledge of the effect of corticosteroids on autophagy in 
IBD, there has been some progress in understanding their effect on 
autophagy in other disease settings.
The clinical response to corticosteroids in UC patients has been 
linked to mTORC1 [Figure  3]. In a transcriptomics study, it was 
observed that miRNA and mRNA profiles in the rectal mucosa of 
UC patients differed between responders and non-responders to 
corticosteroid treatment.55 The mRNA with the most significant 
differential expression between groups was DNA damage-induced 
transcript 4 [DDIT4], an inhibitor of mTORC1 activity, which was 
upregulated in responders after 3 days of corticosteroid treatment. 
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Furthermore, three miRNAs that were differentially expressed in 
responders could potentially target DDIT4.
In the hippocampus of rats, it has also been shown that corti-
costerone treatment affects mTORC1 signalling pathways.56 In 
this study, corticosterone upregulated the expression of DDIT4, as 
well as FK506-binding protein 51 [FKBP51], but downregulated 
DDIT3. DDIT4 and FKBP51 inhibit mTORC1 activity, whereas 
the pro-apoptotic transcription factor DDIT3 is itself regulated by 
mTORC1.56 In agreement, Wang et al.57 found that dexamethasone 
treatment of in vivo skeletal muscle and cultured L6 myoblasts 
increased DDIT4 expression and confirmed that DDIT4 downregu-
lates mTORC1 activity. Another study, investigating the effects of 
dexamethasone treatment on T lymphocytes from healthy donors, 
found that there was a reduction in mTORC1 expression.58 Taken 
together, these studies strongly suggest that the mTORC1 pathway 
and autophagy play an important role in the response to treatment 
with corticosteroids.
Corticosteroid treatment is often associated with secondary 
osteoporosis and several studies have investigated the effects of cor-
ticosteroids on osteocyte cell fate. It has been shown in vitro and 
in vivo that low doses of prednisolone and dexamethasone induce 
autophagy in osteocytes and this is associated with osteocyte via-
bility.59,60 However, higher doses of corticosteroids induce apopto-
sis, suggesting that autophagy may act as a protective mechanism 
against the cytotoxic effects of corticosteroids. 59 Autophagy is also 
activated in spinal cord injuries [SCL] along with apoptosis and 
necrosis; however, rats treated with methylprednisolone exhibited 
decreased autophagy post-SCL.61 The effects of methylprednisolone 
on autophagy in this study may therefore be attributed to direct inhi-
bition of autophagy or to a decrease in inflammation associated with 
injury, which indirectly reduces autophagy.
Corticosteroids are also used to treat lymphoid malignancies by 
blocking cell proliferation and inducing apoptosis in immature T 
cells. It has been shown that glucocorticoids induce autophagy in 
Table 1. IBD drugs mechanism of action.
Drug class Examples Mechanism of action
Corticosteroids Prednisolone, budesonide •  Downregulation of pro-inflammatory cytokines54
•  Interference with NFκB inflammatory signalling54
Aminosalicylates Sulphasalazine, mesalazine •  Scavenging of damaging reactive oxygen species [ROS], upregulation 
of endogenous antioxidant systems, inhibition of leukocyte motility 
and leukotriene and platelet activation, interference with NFκB, 
TNFα, IL-1 and TGF-β, inhibition of nitric oxide formation, 
prevention of mitochondrial damage and colonic epithelial cell 
arrest in S-phase 9
Thiopurines Azathioprine, 6-mercaptopurine •  Inhibition of DNA, RNA and protein synthesis, causing results in 
immune suppression and cytotoxicity75
•  Induce T cell apoptosis through co-stimulation of CD28 due to the 
blockage of RAC1 activation of NFκB76
Immunomodulators Methotrexate, cyclosporin and tacrolimus •  Methotrexate inhibits DNA and RNA synthesis in rapidly dividing 
cells83
•  Cyclosporin and tacrolimus alter IL-2 transcription causing reduced 
T-cell activity83
Biologics [Anti-TNF agents] Infliximab, adalimumab •  Anti-TNFα antibodies neutralize TNFα to prevent pro-inflammatory 
functions
Table 2. Inflammatory bowel disease drugs linked to autophagy modulation.
Drug class Evidence of autophagy modulation
Corticosteroids •  Corticosteroids upregulated mTORC1 inhibitors to induce autophagy in skeletal muscle in vivo, L6 
myoblasts57 and primary human lymphocytes58
• Dexamethasone induced autophagy in T lymphocytes62–64
• Inhibition of autophagy in human monocytes infected with Aspergillus fumigatus65
Aminosalicylates • Sulphasalazine decreased autophagy via NFκB inhibition in an in vivo murine model of cachectic cancer70
•  Sulphasalazine induced autophagic cell death through inhibition of the Akt pathway and activation of the 
ERK pathway in an oral squamous cell carcinoma cell line72
Thiopurines • Autophagy is activated in hepatocytes treated with thiopurines73
•  Increased autophagy in epithelial cells of animal colitis model due to rapid local bacterial conversion of 
thioguanine pro-drug to active metabolite80
Immunomodulators •  Cyclosporin cytotoxicity induced autophagy as a survival process in malignant glioma cells83, primary 
cultured human renal tubular cells and in vivo with rat kidneys84 and in kidney proximal tubule epithelial 
cells85
• Cyclosporin induced autophagic-cell death in a rat pituitary cell line86.
•  Tacrolimus induced autophagy in mouse neuroblastoma and microglial cell lines and in the brains of 
tacrolimus-treated mice90
Biologics [Anti-TNF agents] • Anti-TNF agents can induce reactivation of TB, at least partially due to decreased autophagy 97
•  TNF stimulates autophagy in synovial fibroblasts from rheumatoid arthritis patients,93 in skeletal muscle,94 
in atherosclerotic vascular smooth cells,59 in trophoblastic cells95 and in mouse macrophages96
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immature T cell populations,62 lymphoid cell lines63 and primary leu-
kaemia cells.64 The dexamethasone-induced increase in autophagy 
was also associated with inhibition of mTORC1, possibly through 
regulation of the Src kinase Fyn.62 Swerdlow et al.63 suggested that a 
contributing factor to dexamethasone-induced autophagy could be 
metabolic stress caused by reduced glycolysis and glucose uptake in 
corticosteroid-treated lymphocytes [Figure  3]. Autophagy stimula-
tion by glucocorticoids is relevant for treatment of lymphoid malig-
nancies as it is intimately linked to the induction of apoptosis in 
T lymphocytes.63,64 Corticosteroids are able to induce apoptosis in 
immature T lymphocytes, as these cells lack the inhibitor of apop-
tosis protein Bcl-2. When Bcl-2 was overexpressed in immature T 
lymphocytes, dexamethasone-induced apoptosis was shown to be 
inhibited.63 Although Bcl-2 usually inhibits autophagy by binding 
to Beclin1 [Figure 2], it has been shown that overexpression of Bcl-2 
in immature T lymphocytes can increase autophagy levels, presum-
ably due to inhibition of apoptosis.63 Furthermore, autophagy induc-
tion prolonged the survival of dexamethasone-treated cells, and 
autophagy inhibition decreased survival time.63 In contrast, Laane 
et al 64 found that autophagy played a positive role in dexametha-
sone-induced apoptosis in lymphoid leukaemia cells. In this study, 
dexamethasone induced cell death through promyelocytic leukae-
mia [PML] protein-dependent dephosphorylation of the autophagy 
inhibitor Akt, stimulating the induction of autophagy [Figure 3].
Investigating fungal pathogen elimination in human monocytes 
demonstrated that corticosteroids could block autophagy pro-
tein recruitment to pathogen-containing phagosomes.65 Detection 
of the fungal ligand β-glucan by Dectin-1 receptors triggered Syk 
kinase-dependent production of reactive oxygen species [ROS], 
which stimulate autophagy when cells are infected by Aspergillus 
fumigatus.65 When autophagy was directly inhibited, or cells were 
treated with corticosteroids [in vivo and ex vivo], phagosome matu-
ration [including fusion with the lysosome] and A. fumigatus killing 
were impaired.65 This highlights the importance of autophagy as a 
defence mechanism against fungal infections, but contradicts studies 
suggesting that autophagy is induced by corticosteroid treatment. 
Whereas this study focused on the effects of corticosteroids on xen-
ophagy with A. fumigatus, other studies investigating T lymphocytes 
focused on non-selective macroautophagy induced by cellular stress. 
The contrasting results could be due to differences between the types 
of immune cells investigated, the disease pathogenesis, the types of 
corticosteroids used or the different types of autophagy that were 
investigated, and serves to highlight the cell-type specific nature of 
autophagy and the need to investigate the effect of corticosteroids on 
cell types that are relevant to IBD.
3.4. Aminosalicylates
Aminosalicylates are effective as first-line drugs to induce and maintain 
remission in mild to moderate cases of UC.66 Despite a lack of evidence 
for their efficacy in CD treatment, they are often prescribed as adjuvant 
therapy due to minimal side effects, low cost and chemo-preventative 
properties.3,67 Sulphasalazine or salicylazosulphapyridine [SASP] was 
originally developed for rheumatoid arthritis and contains 5-aminosal-
icyclate [5-ASA] bound to sulphapyridine 68. Sulphapyridine exhibits 
direct antimicrobial activity and treatments with sulphapyridine have 
been linked to alterations in faecal bacterial profiles.69 Sulphapyridine 
has been associated with additional adverse effects,3 leading to the 
development of other forms of aminosalicylates including mesalazine. 
These consist of only the active moiety of SASP and does not contain 
sulphapyridine; pro-drugs of mesalazine, for example balsalazide and 
olsalazine, are also in use.68 The anti-inflammatory activities of 5-ASA 
include the scavenging of damaging ROS, upregulation of endogenous 
antioxidant systems, inhibition of leukocyte motility, leukotriene and 
platelet activation, interference with NFκB, TNFα, IL-1 and TGF-
β, inhibition of nitric oxide formation, prevention of mitochondrial 
damage and colonic epithelial cell-cycle arrest in S-phase.69 In theory, 
many of these activities could directly or indirectly affect autophagy 
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due to a reduction of cellular stress. One study, investigating sul-
phasalazine as an NFκB inhibitor in an in vivo murine model of cancer 
cachexia, reported a decrease in autophagy70 [Figure 3]. This could be 
due to a direct effect of NFκB inhibition, as NFκB signalling regulates 
autophagy in a context-dependent manner,71 or through one or more 
of the other pathways regulated by sulphasalazine. In addition, this 
response may be specific to the disease or to the muscle tissues being 
examined in murine models. In contrast, Han et al.72 reported that 
sulphasalazine treatment in an oral squamous cell carcinoma [OSCC] 
cell line, HSC-4, induced autophagic cell death through inhibition 
of the Akt pathway and activation of the ERK pathway [Figure 3]. 
The seemingly opposing effects of sulphasalazine observed in these 
studies may be due to differences in dosage. Dosage is extremely dif-
ficult to compare between in vitro and in vivo studies; however, it is 
possible that the induction of autophagic cell death observed by Han 
et al.72 may be representative of a concentration range that is cytotoxic.
3.5. Thiopurines
Thiopurines, including azathioprine, 6-mercaptopurine and 6-thio-
guanine, are immunosuppressant drugs used to treat IBD.73 They 
have a relatively slow onset but can maintain remission in moderate 
to severe cases of CD and have also shown some effectiveness for the 
induction of remission.3,74 The commonly used pro-drug azathioprine 
is converted to 6-mercaptopurine [6-MP] by glutathione in the intes-
tinal wall. Through a multi-step enzymatic pathway, the drug is bro-
ken down to thiopurine metabolites, thioguanine nucleotides [TGN] 
and methylmercaptopurine nucleotides [MMPN]. These nucleotides 
act as purine antagonists causing the inhibition of DNA, RNA and 
protein synthesis, which results in immunosuppression and cytotox-
icity.75 Azathioprine can also generate 6-thioguanine GTP, which has 
been shown to induce T cell apoptosis through co-stimulation of the 
CD28 receptor due to blockage of Ras-related C3 botulinum toxin 
substrate [Rac1] activation of NFκB.76 Erythrocyte concentrations of 
thiopurine metabolites are now carefully monitored in many centres, 
to maintain therapeutic levels and to assess adherence, as increases 
in blood concentration have been associated with hepatotoxicity.77 
Other severe adverse effects associated with thiopurines are pancrea-
titis and myelosuppression,3 with 15–20% of patients treated with 
thiopurines having to discontinue treatment due to these side effects.75
Due to the severe adverse effects of thiopurines, a potential 
protective role for autophagy in hepatocytes has been investigated. 
Autophagy is activated in hepatocytes treated with thiopurines, pos-
sibly as a secondary response to the hepatotoxic effects of the drug 
[Figure 3]; however, it could also indicate that autophagy is directly 
modulated to balance immune responses in patients.73,78 Despite the 
lack of understanding of the mechanism of action of thiopurines, it 
has been shown that autophagy has a protective role in hepatocytes 
during thiopurine therapy,73 suggesting that a combination treat-
ment of thiopurines with drugs that induce autophagy may reduce 
their adverse effects, enhancing their efficacy and safety.
A very recent study has correlated ATG16L1 genotype and 
response to thiopurines in two IBD cohorts and found that the 
ATG16L1 risk variant associates with response to thiopurine treat-
ment specifically in patients with CD but not with UC.79 Furthermore, 
a defect in the autophagosomal regulation of active Rac1, a member 
of the Rho family of GTPases linked to the regulation of diverse cel-
lular functions including cytoskeletal rearrangement, underlies the 
association between ATG16L1 and CD through decreased myeloid 
cell migration.79 As thiopurine can inhibit Rac1 activity, the authors 
suggest that ATG16L1 genotyping may be used to identify patients 
who would benefit from thiopurine treatment. In another new study, 
the rapid local bacterial conversion of thioguanine pro-drug to active 
metabolite was shown to augment autophagy in epithelial cells, 
resulting in increased intracellular bacterial killing and decreased 
intestinal inflammation and immune activation in spontaneous and 
induced animal colitis models.80
3.6. Methotrexate, cyclosporin and tacrolimus
Methotrexate, cyclosporin and tacrolimus are immunomodulatory 
drugs used mainly as second-line treatments to maintain remission in 
severe, steroid-refractory CD,81 with more recent evidence suggesting 
a role for tacrolimus in UC.82 Methotrexate inhibits DNA and RNA 
synthesis in rapidly dividing cells, and cyclosporin and tacrolimus 
alter IL-2 transcription causing reduced T cell activity.83 Although 
some evidence suggests that cyclosporin and tacrolimus modulate 
autophagy as part of their mechanism of action, no link has been 
identified between methotrexate and autophagy modulation.
Cyclosporin, originally used to prevent organ transplant rejec-
tion, acts by blocking lymphocyte and other immune cell activation.83 
As this drug has very cytotoxic effects, several studies have shown 
that treatment with cyclosporin can induce autophagy in response 
to the toxicity either as a survival process or as part of a cell death 
mechanism.83–86 Toxic levels of cyclosporin induced autophagy in 
vivo and in vitro in malignant glioma cells. 83 This was accompanied 
by mTORC1 inhibition and an ER stress response, with blockage 
of ER signalling decreasing accumulation of the autophagy marker 
LC3-II83 [Figure 3]. Furthermore, when autophagy is inhibited by 
blocking ULK1, ATG5 or ATG7, cyclosporin-induced cell death was 
shown to increase.83 These results suggest that autophagy is induced 
as a protective response to the cytotoxic effects of cyclosporin.
In a study of cyclosporin-induced nephrotoxicity, ER stress-
dependent autophagy induction [Figure 3] has been demonstrated 
in primary cultured human renal tubular cells and in vivo within 
rat kidneys.84 In addition, cyclosporin can cause chronic metabolic 
stress, which leads to autophagy induction in kidney proximal 
tubule epithelial cells.85 In this study, autophagy-competent cells 
allow for metabolic adaptation to cyclosporin treatment, whereas 
autophagy deficiency resulted in cyclosporin-induced deterioration 
of the tricarboxylic acid [TCA] cycle and the overall energy status of 
the cell. In a rat pituitary cell line model, cyclosporin induced apop-
tosis and autophagic-cell death in a dose-dependent manner.86 From 
these studies, it appears that autophagy is stimulated by cyclosporin 
only as a secondary response to the drug’s cytotoxic effects.
The mechanism of action of tacrolimus, also known as FK506, is 
similar to that of cyclosporin as both drugs inhibit the protein phos-
phatase calcineurin to block T cell function and IL-2 transcription. 
FK506 inhibits calcineurin by forming a complex with the immuno-
philin FKBP12 [FK506 binding protein], which is involved in immu-
noregulation.87 FKBP12 is also the direct target of rapamycin, an 
inhibitor of mTORC1.
A recent study by Ge et al.88 investigating a novel activator of 
mTORC1, 3-benzyl-5-[[2-nitrophenoxy] methyl]–dihydrofuran-
2[3H]-one [3BDO], demonstrated that 3BDO could activate 
mTORC1 by occupying the rapamycin-binding site in FKBP12.89 
This study suggested that FK506, through a mechanism involving 
the formation of an FK506-FKBP12 complex, has the potential to 
act as an mTORC1 activator and autophagy inhibitor [Figure 3]. 
In another study investigating the use of FK506 as a novel thera-
peutic for prion infections, FK506 was shown to induce autophagy 
in mouse neuroblastoma [N2a58] and mouse microglial [MG20] 
cell lines and in the brains of mice.90 FK506 treatment significantly 
increased LC3-II, ATG5, ATG7 and autolysosome formation, 
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concomitant with decreased prion protein levels in cell cultures and 
increased survival of mice due to delayed accumulation of prion 
proteins.90
3.7. Biologic agents
Overproduction of pro-inflammatory cytokines and chemokines 
are a common feature associated with inflammatory diseases. 
Monoclonal antibodies that target and neutralise cytokines such as 
TNFα, IL-12, IL-23, IL-21, IL-22, IL-32 and IFN-γ, with a view to 
decreasing pro-inflammatory signaling, are used for the treatment of 
IBD.91 These biologic agents are usually reserved for the treatment of 
refractory CD or steroid-dependent patients to induce and maintain 
remission.
The most commonly used biologic agent for IBD is the anti-
TNFα antibody, infliximab. Other anti-TNFα treatments approved 
for treatment of IBD patients include adalimumab, golimumab for 
UC only, and certolizumab pegol, which is approved in the USA, 
Switzerland and Russia. Anti-TNFα biosimilars, which are cheaper 
versions of licensed biologic agents whose patents have now expired, 
have also recently been developed.92
TNFα plays a major role in modulating the inflammatory response, 
and while the effects of TNFα have been extensively studied in a vari-
ety of cell types, its mechanism of action in the gut remains unknown. 
One confirmed effect of TNFα is the modulation of autophagy, which 
has been observed in synovial fibroblasts from rheumatoid arthritis 
patients,93 in skeletal muscle,94 in atherosclerotic vascular smooth 
cells59 and in trophoblastic cells.95 The effect of TNFα on mitophagy, a 
specific type of autophagy that involves the degradation of mitochon-
drial proteins and the mitochondrial organelle, has also been demon-
strated in mouse macrophages.96 This study found that macrophages 
activated by TNFα have increased mitophagy, resulting in increased 
mitochondrial protein degradation and presentation to T cells via 
MHC I on the cell surface of the macrophages. As macrophages play 
a crucial role in innate immunity and inflammation within the gas-
trointestinal tract, further investigation of the effects of TNFα on 
autophagy in this cell type will be particularly relevant to IBD.
Taken together, these studies suggest that anti-TNF agents 
would inhibit autophagy [Figure 3]. Although there are no studies 
that have directly confirmed this, there is support for this hypoth-
esis; anti-TNF agents can induce reactivation of Mycobacterium 
tuberculosis, at least partially due to decreased autophagy.97 This 
effect is likely due to the protective antibacterial and anti-inflam-
matory roles of autophagy in epithelial cells infected with this non-
motile bacillus.98 It is worth noting however, that TNFα can also 
have inhibitory effects on autophagy in some contexts. A study 
investigating the effects of elevated TNFα on congestive heart 
failure in H9C2 rat cardiomyoblasts found that, although TNFα 
induces autophagy, autophagic protein degradation is disrupted, 
as evidenced by accumulation of p62 and increased ubiquitin-pro-
teasome pathway activity.99 Additionally, Andrographis paniculata 
plant extract [HMPL-400], which is currently being studied in IBD 
trials for reduction of TNFα, IL-1β, IFN-γ and IL-22 expression, 
has been shown to inhibit autophagy in cancer.100 This may be due 
to the reduction of cytokines or another mechanism affected by 
HMPL-400.
4. Conclusions
The modulation of autophagy represents an exciting therapeutic 
option for the treatment of IBD, and evidence is already emerg-
ing that drugs currently used for the treatment of IBD can affect 
the autophagy pathway. The cross-talk between autophagy and 
ER stress offers new options for how IBD could be targeted, and 
combination treatments aimed at modulating both the UPR and 
autophagy warrant further investigation. However, to date there is 
little evidence that modulation of autophagy can be directly linked 
to amelioration of disease, with only one published case study of the 
mTORC1 inhibitor sirolimus [rapamycin] improving symptoms and 
healing in a patient with severe refractory CD.101 A major caveat is 
that autophagy is cell type specific, which makes it difficult to mech-
anistically link drug-induced autophagy to modulation of disease. 
Irrespective of this there is a pressing need to determine how these 
drugs modulate the autophagy pathway, specifically in patients with 
known mutations in the genes regulating the autophagy apparatus, 
and this must begin with consolidating studies in an in vitro setting 
in cell types directly relevant to IBD. A more comprehensive under-
standing of their mechanisms of action will undoubtedly allow for 
better-informed decisions regarding suitability of drug treatment for 
IBD on a patient-to-patient basis.
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